This program offers bone marrow from deceased organ and tissue donors (Ossium's HPC, Marrow) for patients needing a bone marrow transplant (BMT). It's for people aged 12 to 80 whose doctor believes a transplant is right for them and that the benefits outweigh the risks. This program helps patients who might not be able to join the PRESERVE trial. The main goal is to see if white blood cells (neutrophils) recover within 28 days after the transplant. This is an observational study, meaning researchers are watching what happens rather than testing a new drug. The current status of the program is unclear.

Study design

This is an observational study with a planned enrollment of 10 participants. It is not specified if it is randomized or blinded.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured at 28 days, indicating follow-up for at least this duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.